Related Experiment Video
Updated: Mar 11, 2026
06:20
Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer
Published on: October 4, 2022
4.1K
Molecular Pathogenesis of Pancreatic Cancer
Progress in Molecular Biology and Translational Science
|November 21, 2016
Summary
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer driven by KRAS mutations and other genetic alterations. Understanding its molecular subtypes and pathogenesis is key to developing new therapies for this challenging disease.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with poor prognosis and limited treatment options.
- Its genetic and phenotypic heterogeneity presents challenges for developing effective therapies.
- Common genetic drivers include KRAS mutations and inactivating mutations in tumor suppressor genes like CDKN2A/p16, TP53, and SMAD4.
Purpose of the Study:
- To provide an overview of pancreatic ductal adenocarcinoma (PDAC) pathogenesis.
- To explore the genetic and molecular underpinnings of PDAC.
- To discuss novel therapeutic opportunities for treating PDAC.
Main Methods:
- Review of current knowledge on PDAC genetics and molecular biology.
- Analysis of gene expression profiling data for PDAC classification.
- Examination of the role of key oncogenes and tumor suppressor genes in PDAC development.
Main Results:
- PDAC originates from pancreatic ductal epithelial cells.
- Activating KRAS mutations are common and drive tumor initiation.
- Inactivating mutations in CDKN2A/p16, TP53, and SMAD4 cooperate with KRAS.
- PDAC can be classified into 3-4 molecular subtypes with distinct characteristics.
Conclusions:
- PDAC pathogenesis is complex, involving multiple genetic alterations.
- Molecular subtyping offers insights into PDAC heterogeneity.
- Further research into PDAC's genetic and molecular landscape is crucial for developing targeted therapies.
Related Concept Videos
02:07Tumor Progression
7.7K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.7K
01:35Cancer Cell Migration through Invadopodia
3.4K
Invadosome is a broad category of cell surface structures with proteolytic activity that degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...
3.4K
03:03mTOR Signaling and Cancer Progression
5.0K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
5.0K
02:30Metastasis
6.7K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.7K
01:24Chronic Pancreatitis I: Introduction
830
The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
830
02:21Cancers Originate from Somatic Mutations in a Single Cell
15.3K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
15.3K